Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.
ABC News · 1d
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Reuters · 3d
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk Skeptic Finally Upgrades Stock
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results